Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jul 31;12(4):657-677.
doi: 10.5599/admet.2366. eCollection 2024.

Optimizing gefitinib nanoliposomes by Box-Behnken design and coating with chitosan: A sequential approach for enhanced drug delivery

Seema Rohilla  1 , Rajendra Awasthi  2 , Ankur Rohilla  3 , Sachin Kumar Singh  4 , Dinesh Kumar Chellappan  5 , Kamal Dua  6   7 , Harish Dureja  7   8   9
Affiliations

Optimizing gefitinib nanoliposomes by Box-Behnken design and coating with chitosan: A sequential approach for enhanced drug delivery

Seema Rohilla et al. ADMET DMPK. .

Abstract

Background and purpose: This study aimed to improve the stability and prolonged gefitinib release from the nanoliposomes.

Experimental approach: Nanoliposomes were prepared by reverse-phase evaporation and optimized using Box-Behnken design to investigate the influence of sonication time (X 1), tween 80 / soya phosphatidylcholine ratio (X 2), and cholesterol/soya phosphatidylcholine ratio (X 3) on nanoliposomes.

Key results: Optimized nanoliposomes were quasi-spherical shaped, with a mean dimension of 93.2 nm and an encapsulation efficiency of 87.56±0.17 %. Surface decoration of the optimized batch was done using different concentrations of chitosan. The optimal chitosan concentration required to adorn the nanoliposome surface was 0.01 %. In comparison to unadorned nanoliposomes (82.16±0.65 %), adorned nanoliposomes (78.04±0.35 %) released the drug consistently over 24 h via Fickian diffusion. The IC50 values for surface-adorned nanoliposomes in A549 and H1299 cells were 6.53±0.75 and 4.73±0.46 μM, respectively. Cytotoxicity of the surface-decorated nanoliposomes may be due to their higher zeta potential and prolonged drug release. At the end of the sixth month, the samples stored at 4 °C were more stable than those stored at 25 °C and 45 °C. The stability of plain nanoliposomes has increased after chitosan coating. Thus, by using different concentrations of chitosan solution as coating material, we can develop a suitable sustained drug-release surface-adorned nanoliposomal formulation.

Conclusion: The developed nanoliposomes may offer a new path for melanoma clinics.

Keywords: Liposomes; pulmonary cancer; response surface methodology.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: The authors declared that there are no conflicts of interest.

Figures

Figure 1.
Figure 1.
(I) Upshot plot of coefficients on encapsulation efficiency [A1, A2, and A3 are coefficients of main effects (X1, X2, and X3); A4, A5, and A6 are coefficients of interaction terms (X1X2, X2X3, and X1X3); and A7, A8, and A9 are coefficients of square terms (X12, X22, X32)]. (II) Upshot plot of particle size [(B1, B2, and B3 are coefficients of main effects (X1, X2, and X3); B4, B5, and B6 are coefficients of interaction terms (X1X2, X2X3, and X1X3); and B7, B8, and B9 are coefficients of square terms (X12, X22, X32)].
Figure 2.
Figure 2.
Response surface plots and contour plots showing the influence of level of sonication time, Tween 80/soya lecithin ratio, and cholesterol/soya lecithin ratio on mean particle size (I, II) and encapsulation efficiency (III, IV).
Figure 3.
Figure 3.
Overlay of DSC analysis of gefitinib, chitosan, cholesterol, soya lecithin, and uncoated nanoliposomal formulation (I), and chitosan-coated optimized nanoliposomes (formulation NG13) (II).
Figure 4.
Figure 4.
Overlay of FTIR spectra of cholesterol (I), chitosan (II), soya lecithin (III), and (IV) gefitinib.
Figure 5.
Figure 5.
Overlay of FTIR spectra of unadorned nanoliposomal formulation (I); coated nanoliposomal formulation (II).
Figure 6.
Figure 6.
Transmission electron micrographs of unadorned nanoliposomes (I), surface adorned nanoliposomes (II).
Figure 7.
Figure 7.
Comparison of in vitro release of drug from pure drug dispersion, optimized uncoated nanoliposomes and chitosan-coated nanoliposomes (I) in simulated gastrointestinal fluid, (II) in acetate buffer pH 4.0, and (III) in simulated intestinal fluid pH 6.8. Data presents mean ± SD, n = 3.
Figure 8.
Figure 8.
IC50 value of pure gefitinib, simple nanoliposomes (uncoated), and surface-adorned nanoliposomes.
See this image and copyright information in PMC

References

    1. Cryer A.M., Thorley A.J.. Nanotechnology in the diagnosis and treatment of lung cancer. Pharmacology & Therapeutics 198 (2019) 189-205. https://doi.org/10.1016/j.pharmthera.2019.02.010 10.1016/j.pharmthera.2019.02.010. - DOI - PubMed
    1. Rivera M.P., Mehta A.C., Wahidi M.M.. Establishing the diagnosis of lung cancer: Diagnosis and management of lung cancer. Chest 143 (2013) e142S-e165S. https://doi.org/10.1378/chest.12-2353 10.1378/chest.12-2353. - DOI - PubMed
    1. Hochhegger B., Alves G.R., Irion K.L., Fritscher C.C., Fritscher L.G., Concatto N.H., Marchiori E.. PET/CT imaging in lung cancer: Indications and findings. Jornal Brasileiro de Pneumologia 41 (2015) 264-274. https://doi.org/10.1590/S1806-37132015000004479 10.1590/S1806-37132015000004479. - DOI - PMC - PubMed
    1. Carrasco-Esteban E., Dominguez-Rullan J.A., Barrionuevo-Castillo P., Pelari-Mici L., Leaman O., Sastre-Gallego S., López-Campos F.. Current role of nanoparticles in the treatment of lung cancer. Journal of Clinical and Translational Research 7 (2021) 140-155. https://doi.org/10.18053/jctres.07.202102.005 10.18053/jctres.07.202102.005. - DOI - PMC - PubMed
    1. Miller Y.E.. Pathogenesis of lung cancer. American Journal of Respiratory Cell and Molecular Biology 33 (2005) 216-223. https://doi.org/10.1165/rcmb.2005-0158OE 10.1165/rcmb.2005-0158OE. - DOI - PMC - PubMed

LinkOut - more resources